Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Platelet-derived Growth factor-BB (PDGF-BB)
100%
Vascular Smooth muscle Cells
100%
Dasatinib
100%
BMS-354825
100%
Induced Response
100%
Platelet-derived Growth Factor Receptor (PDGFR)
40%
Restenosis
20%
Imatinib
20%
Human Aortic Smooth muscle Cells (HASMCs)
20%
Clinical Trials
10%
In Cancer
10%
Cancer Patients
10%
Potent Inhibitor
10%
Mitogen
10%
Inhibition Rate
10%
Smooth muscle Cells
10%
Receptor Tyrosine Kinase
10%
Cellular Level
10%
BCR-ABL Inhibitors
10%
STI571
10%
Tyrosine Kinase Inhibitor
10%
Gleevec
10%
Balloon Angioplasty
10%
Concentration-dependent
10%
Novel Protein
10%
Primary Culture
10%
Receptor Antagonist
10%
Obstructive Disease
10%
ERK2
10%
In Vitro Activity
10%
Receptor Activation
10%
New Therapies
10%
Long-term Benefit
10%
Stenting Procedures
10%
Nanomolar Concentrations
10%
Orally Bioavailable
10%
Tyrosine Kinase Activity
10%
Src Tyrosine Kinase
10%
Cell Activity
10%
Abnormal Migration
10%
Abnormal Proliferation
10%
Medicine and Dentistry
Platelet Derived Growth Factor
100%
Vascular Smooth Muscle Cell
100%
Dasatinib
100%
Imatinib
57%
Platelet Derived Growth Factor Receptor
57%
Protein Tyrosine Kinase
28%
Restenosis
28%
Aortic Smooth Muscle Cell
28%
Malignant Neoplasm
14%
Clinical Trial
14%
Stenting
14%
In Vitro
14%
Arteriosclerosis Obliterans
14%
Smooth Muscle Cell
14%
Tyrosine-Kinase Inhibitor
14%
Mitogenic Agent
14%
Percutaneous Transluminal Angioplasty
14%
Cell Activity
14%
Primary Culture
14%
Bcr-Abl Tyrosine-Kinase Inhibitor
14%
Protein Kinase B
14%
Pharmacology, Toxicology and Pharmaceutical Science
Platelet Derived Growth Factor
100%
Dasatinib
100%
Platelet Derived Growth Factor Receptor
66%
Imatinib
66%
Protein Tyrosine Kinase Inhibitor
33%
Protein Tyrosine Kinase
33%
Restenosis
33%
Clinical Trial
16%
Malignant Neoplasm
16%
Mitogenic Agent
16%
Abelson Kinase
16%
Primary Culture
16%
Peripheral Occlusive Artery Disease
16%
Biochemistry, Genetics and Molecular Biology
Platelet-Derived Growth Factor
100%
Dasatinib
100%
Platelet-Derived Growth Factor Receptor
66%
Imatinib
66%
Receptor Tyrosine Kinase
50%
Clinical Trial
16%
Bcr-Abl Tyrosine-Kinase Inhibitor
16%
STAT3
16%
Tyrosine Kinase
16%
Primary Culture
16%
Cell Level
16%
Cell Activity
16%
Protein Kinase B
16%